 |
| |
| Apr-12-19 | Initiated |
Evercore ISI |
Outperform |
|
|
| Mar-06-19 | Upgrade |
Evercore ISI |
In-line → Outperform |
|
|
| Mar-05-19 | Upgrade |
Morgan Stanley |
Equal-Weight → Overweight |
|
|
| Jan-23-19 | Initiated |
UBS |
Neutral |
$87 |
|
| Oct-01-18 | Initiated |
Cantor Fitzgerald |
Overweight |
$135 |
|
| Aug-13-18 | Reiterated |
Stifel |
Buy |
$125 → $123 |
|
| Aug-07-18 | Upgrade |
Stifel |
Hold → Buy |
$95 → $125 |
|
| May-04-18 | Reiterated |
Stifel |
Hold |
$107 → $95 |
|
| Mar-28-18 | Initiated |
Evercore ISI |
In-line |
|
|
| Mar-26-18 | Reiterated |
JMP Securities |
Mkt Outperform |
$169 → $207 |
|
| Feb-16-18 | Reiterated |
B. Riley FBR, Inc. |
Buy |
$205 → $200 |
|
| Jan-08-18 | Reiterated |
B. Riley FBR, Inc. |
Buy |
$220 → $205 |
|
| Nov-09-17 | Upgrade |
JP Morgan |
Neutral → Overweight |
|
|
| Nov-08-17 | Reiterated |
Barclays |
Overweight |
$127 → $158 |
|
| Nov-08-17 | Reiterated |
B. Riley FBR, Inc. |
Buy |
$240 → $220 |
|
| Nov-03-17 | Reiterated |
Needham |
Buy |
$125 → $152 |
|
| Nov-02-17 | Reiterated |
B. Riley FBR, Inc. |
Buy |
$150 → $240 |
|
| Oct-30-17 | Initiated |
FBR & Co. |
Buy |
$150 |
|
| Oct-02-17 | Upgrade |
Goldman |
Neutral → Buy |
|
|
| Sep-21-17 | Reiterated |
Needham |
Buy |
$85 → $125 |
|
|
|
| Apr-19-19 10:41AM | Here is What Hedge Funds Think About Alnylam Pharmaceuticals, Inc. (ALNY) Insider Monkey |
| Apr-16-19 07:13PM | Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran Zacks |
| 07:27AM | Is Alnylam Pharmaceuticals a Buy Now? Motley Fool |
| Apr-15-19 04:49PM | Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran Zacks |
| 07:00AM | Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study Business Wire |
| Apr-12-19 06:01PM | Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria Business Wire |
| 07:23AM | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks |
| Apr-11-19 09:27AM | 4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics Zacks |
| Apr-10-19 09:20AM | Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More Zacks |
| Apr-09-19 09:03AM | Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics Zacks |
| Apr-08-19 01:55PM | Regeneron, Alnylam Strike $1B Collaboration For RNAi-based Therapeutics Benzinga |
| 11:13AM | Regeneron forays into gene-silencing therapies with Alnylam tie-up Reuters |
| 09:10AM | Alnylam trades partner Sanofi for Regeneron in $800M deal American City Business Journals |
| 08:50AM | What Do Analysts Think About Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Earnings Trajectory? Simply Wall St. |
| 07:11AM | Alnylam, Regeneron to partner for RNAi treatments Reuters |
| 07:00AM | Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases PR Newswire |
| 07:00AM | Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases Business Wire |
| 01:00AM | Alnylam and Sanofi Conclude Research and Option Phase of 2014 RNAi Therapeutics Collaboration Business Wire |
| Mar-30-19 11:31AM | 2 Biotechs With Big Dates in April Motley Fool |
| Mar-27-19 07:00AM | Alnylam to Present Givosiran Phase 3 Data at the European Association for the Study of the Liver (EASL) International Liver Congress Business Wire |
| Mar-20-19 07:07AM | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks |
| Mar-18-19 06:51PM | Alnylam's (ALNY) Impressive Pipeline Drives Share Price Zacks |
| Mar-12-19 09:59AM | Alnylam Files Application for Hypertension Candidate in UK Zacks |
| Mar-11-19 07:00AM | Alnylam Submits CTA Application for ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension in High Unmet Need Settings Business Wire +5.50% |
| Mar-09-19 08:31AM | Why Is Alnylam (ALNY) Up 3.1% Since Last Earnings Report? Zacks |
| Mar-07-19 04:00PM | Alnylam to Webcast Presentation at Cowen & Company 39th Annual Health Care Conference Business Wire |
| 09:00AM | Alnylam Stock Down Despite Positive Phase III Givosiran Data Zacks |
| Mar-06-19 04:10PM | Could This Biotech Sacrifice A Buy Point On Drug Safety Questions? Investor's Business Daily |
| 11:06AM | Side effects of Alnylam's gene-silencing drug raise concerns, shares slip Reuters |
| 09:12AM | Alnylam Pharmaceuticals stock down 7.5% after announcing results of Phase 3 givosiran trial MarketWatch |
| 08:20AM | After trial success, Alnylam plans to seek FDA approval for 2nd drug American City Business Journals |
| 07:08AM | Alnylam's gene-silencing drug meets main goal in late-stage study Reuters |
| 07:00AM | Alnylam Reports Positive Topline Results from ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria Business Wire |
| Mar-04-19 09:19AM | Can This Biotech Puppy Run With the Big Dogs? Motley Fool |
| Feb-28-19 09:50AM | Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus Zacks |
| 07:00AM | Alnylam Announces Recipients of First Annual Advocacy for Impact Grants Program Business Wire |
| Feb-25-19 06:43AM | FDA panel says Karyopharm's cancer drug shows 'significant toxicity' American City Business Journals |
| Feb-14-19 06:48PM | Alnylam Pharmaceuticals Inc (ALNY) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com |
| 12:01PM | Is Moderna a Buy? Motley Fool |
| Feb-12-19 10:04AM | Alnylam Pharmaceuticals Is Launched and Ready for More Motley Fool |
| 08:10AM | Detailed Research: Economic Perspectives on DXC Technology, AMC Networks, SunCoke Energy Partners, Alnylam Pharmaceuticals, Amtech, and Diamond Hill Investment Group What Drives Growth in Today's Competitive Landscape GlobeNewswire |
| Feb-11-19 11:14AM | Edited Transcript of ALNY earnings conference call or presentation 7-Feb-19 9:30pm GMT Thomson Reuters StreetEvents |
| Feb-08-19 09:17AM | The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs Benzinga |
| 07:47AM | Alnylam's (ALNY) Q4 Earnings and Revenues Beat Estimates Zacks |
| Feb-07-19 11:15PM | Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2018 Earnings Conference Call Transcript Motley Fool |
| 06:15PM | Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates Zacks |
| 05:23PM | Alnylam: 4Q Earnings Snapshot Associated Press |
| 04:00PM | Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Recent Period Activity Business Wire |
| Feb-06-19 05:00PM | Alnylam Announces Publication of Phase 1 Givosiran Data in The New England Journal of Medicine Business Wire |
| Feb-04-19 04:00PM | Alnylam to Webcast Presentations at Upcoming February Investor Conferences Business Wire |
| Jan-31-19 04:00PM | Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2018 Financial Results Business Wire |
| 07:55AM | Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sarepta Therapeutics ACCESSWIRE |
| Jan-24-19 10:51AM | The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio Zacks |
| Jan-23-19 10:48AM | 5 Best Biotech Bets Likely to Outperform Estimates in Q4 Zacks |
| 09:12AM | Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs Zacks |
| Jan-22-19 07:58AM | Alnylam & Medison Partner to Market RNAi Products in Israel Zacks |
| Jan-21-19 03:00AM | Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel Business Wire |
| Jan-16-19 07:30AM | New Research Coverage Highlights Gentex, Tenneco, Mercury General, MGM Resorts International, ResMed, and Alnylam Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire |
| Jan-15-19 08:00AM | Pfizer Gets FDA's Priority Review for Rare Disease Candidate Zacks |
| Jan-14-19 09:13PM | Alnylam Pharmaceuticals Prices Public Offering of Common Stock Business Wire -5.72% |
| 04:23PM | This Biotech Stock Plunged On Its Looming Rivalry With Pfizer Investor's Business Daily |
| 04:04PM | Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire |
| Jan-09-19 09:33AM | Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus Zacks |
| Jan-08-19 04:52PM | 3 Things Alnylam's Management Wants You to Know Motley Fool |
| 09:54AM | Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4 Zacks |
| Jan-07-19 09:58AM | Sales of Alnylam's first drug beat expectations in final quarter of 2018 American City Business Journals +8.75% |
| 08:00AM | Alnylam Announces Unaudited Fourth Quarter 2018 Global Revenues for ONPATTRO® (patisiran) and Provides Additional Commercial Updates Business Wire |
| Jan-02-19 03:48PM | Cannabis, Migraines, Gene-Silencing: FDA Approvals Hit High Note In 2018 Investor's Business Daily |
| Dec-28-18 07:00AM | Alnylam to Webcast Presentation at 37th Annual J.P. Morgan Healthcare Conference Business Wire |
| Dec-27-18 08:37AM | Alnylam (ALNY) Surges: Stock Moves 8.7% Higher Zacks |
| Dec-20-18 05:13PM | Robbins Arroyo LLP: Alnylam Pharmaceuticals, Inc. (ALNY) Sued by Shareholders Business Wire |
| Dec-18-18 09:29AM | RNAi Goes Big-Time in 2018 Motley Fool |
| 08:55AM | Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved Benzinga |
| Dec-13-18 10:13AM | Top 10 Healthcare Stories of 2018 Motley Fool |
| 07:00AM | Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Array BioPharma ACCESSWIRE |
| Dec-10-18 07:58AM | 5 Top Drug/Biotech Merger & Acquisition Targets for 2019 Zacks |
| 02:00AM | Alnylam Announces Settlement of Litigation with Silence Therapeutics Business Wire |
| Dec-08-18 12:44PM | Hedge Funds Are Dumping Alnylam Pharmaceuticals, Inc. (ALNY) Insider Monkey |
| Dec-07-18 06:11PM | [$$] Moderna IPO Marks Milestone for New Biotech Market The Wall Street Journal -6.71% |
| 12:20PM | Modernas Rich IPO Valuation Raises the Stakes for Investors Bloomberg |
| Dec-06-18 08:15AM | Recent Analysis Shows Microsoft, Alnylam Pharmaceuticals, F5 Networks, Green Plains Partners LP, Itron, and Progress Software Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire |
| 07:00AM | Alnylam Provides R&D Updates and Announces 2019 Product and Pipeline Goals at R&D Day Business Wire |
| Nov-30-18 06:55AM | Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sage Therapeutics ACCESSWIRE |
| Nov-29-18 05:30PM | Why Pfizer Could Lead These Two Biotech Stocks In Tackling Amyloidosis Investor's Business Daily |
| 03:28PM | Alnylam CEO on drug prices: Has to be some type of reward... CNBC Videos |
| 08:00AM | Alnylam to Webcast R&D Day Business Wire |
| Nov-27-18 03:41PM | Alnylam, Vir Begin Phase I/II Study on Hepatitis B Candidate Zacks |
| 02:48PM | Why Alnylam Pharmaceuticals Incs (NASDAQ:ALNY) CEO Pay Matters To You Simply Wall St. |
| Nov-26-18 10:00AM | DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action Against Alnylam Pharmaceuticals, Inc. (ALNY) & Lead Plaintiff Deadline November 26, 2018 GlobeNewswire +6.83% |
| 08:00AM | DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire |
| 07:00AM | Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218 Business Wire |
| Nov-25-18 06:07PM | DEADLINE TOMORROW: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire |
| 10:17AM | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TGTX, ALNY, CHGG, CWH and DY GlobeNewswire |
| 09:00AM | ALNY NOV 26 DEADLINE: Rosen Law Firm Reminds Alnylam Pharmaceuticals, Inc. Investors of Important Deadline in Class Action GlobeNewswire |
| 08:00AM | MONDAY DEADLINE: Kaskela Law LLC Announces Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ALNY GlobeNewswire |
| Nov-24-18 06:42PM | TUESDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
| 01:50PM | SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. ALNY ACCESSWIRE |
| Nov-23-18 11:41AM | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm ACCESSWIRE |
| 10:30AM | DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire |
| 10:00AM | SHAREHOLDER ALERT: APOG TGTX ALNY ACHC JT HON DY ALGN RYAAY MGI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire |
|
|
|
|
| Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The company's development programs include Vutrisiran, an investigational RNAi therapeutic targeting transthyretin that is in Phase III trials for the treatment of transthyretin-mediated amyloidosis; Givosiran that is in Phase III trials to treat acute hepatic porphyrias; and Lumasiran, an investigational RNAi therapeutic, which is in Phase III clinical trials for glycolate oxidase to treat primary hyperoxaluria type 1. It is also developing Inclisiran, an investigational RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9 that is in Phase III clinical trials for the treatment of hypercholesterolemia; and Fitusiran, an investigational RNAi therapeutic that is in Phase III clinical trials for treating hemophilia A and B with or without inhibitors. In addition, the company engages in the development of Cemdisiran for complement-mediated diseases; ALN-AAT02 to treat alpha-1 anti-trypsin deficiency-associated liver disease; ALN-HBV02 for treating chronic hepatitis B virus infection; and other earlier-stage programs. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| SHARP PHILIP A | Director | Apr 15 | Option Exercise | 22.09 | 15,000 | 331,350 | 250,633 | Apr 17 04:05 PM | | SHARP PHILIP A | Director | Apr 15 | Sale | 88.23 | 15,000 | 1,323,442 | 235,633 | Apr 17 04:05 PM | | MARAGANORE JOHN | Chief Executive Officer | Nov 21 | Option Exercise | 21.35 | 98,636 | 2,105,879 | 249,933 | Nov 26 04:11 PM | | Greenstreet Yvonne | EVP, Chief Operating Officer | Aug 30 | Sale | 120.00 | 2,500 | 300,000 | 1,916 | Sep 04 04:15 PM | | MARAGANORE JOHN | Chief Executive Officer | Jul 25 | Option Exercise | 21.35 | 50,000 | 1,067,500 | 201,297 | Jul 27 04:07 PM | | MARAGANORE JOHN | Chief Executive Officer | Jul 25 | Sale | 105.39 | 50,000 | 5,269,457 | 151,297 | Jul 27 04:07 PM | | KEATING LAURIE | SVP, GC & Secretary | Jun 20 | Option Exercise | 42.22 | 1,563 | 65,990 | 16,063 | Jun 22 04:20 PM | | KEATING LAURIE | SVP, GC & Secretary | Jun 20 | Sale | 105.04 | 1,563 | 164,178 | 14,500 | Jun 22 04:20 PM | | CLARKE JOHN K | Director | May 31 | Option Exercise | 27.28 | 15,000 | 409,200 | 23,891 | Jun 04 04:25 PM | | CLARKE JOHN K | Director | May 31 | Sale | 100.31 | 15,000 | 1,504,678 | 8,891 | Jun 04 04:25 PM |
|
|
|
|
|
|
